Abstract Library

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,

#3515 PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy

Introduction: Long-acting (LA) SSA therapy is a common long-term treatment for NETs, but real-world data on patients’ injection experience using the latest LA SSA designs/formulations are limited.

Conference:

Presenting Author: O'Toole D

Authors: O'Toole D, Prebtani A, Webb S, Houchard A, Gueguen D,

Keywords: acromegaly, injection site pain, lanreotide autogel/depot, neuroendocrine tumor, octreotide long-acting release syringe, patient survey,

#3380 Dose selection for paltusotine, a once daily oral nonpeptide, somatostatin receptor 2 ligand, for the treatment of patients with Carcinoid Syndrome (CS)

Introduction: Long-acting somatostatin receptor ligands (LA-SRLs) are first line therapy for neuroendocrine tumor (NET) syndromes including acromegaly and the carcinoid syndrome (CS). In acromegaly, two phase 2 studies (NCT 03789656 and 03792555) suggested that patients injected with SRLs can switch to once daily orally bioavailable paltusotine (CRN00808), a nonpeptide, small molecule, somatostatin type 2 (SST2) receptor ligand (SRL), while maintaining stable serum IGF-1 levels. However, CS patients may require higher doses of an orally administered drug due to maldigestion commonly associated with the syndrome or its treatment and the pharmacokinetics (clearance and volume of distribution) of paltusotine may differ between CS and acromegaly because of differences in metabolic capacity of the liver and body composition.

Conference:

Presenting Author:

Authors: Lagast H, Madan A, Metz D, Luo R, Struthers S,

Keywords: neuroendocrine tumor, carcinoid syndrome, paltusotine, somatostatine receptor ligand, dose-response, exposure-response,

#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme

Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Teulé A, Simó-Servat A, Serrano R, Venegas E,

Keywords: Lanreotide, Satisfaction, Home training,

#2802 EvAluation de Satisfaction Infirmière (Nurse Satisfaction Evaluation). Observational Study of the Preparation and Intramuscular Administration of the Previous and New Long-Acting Release Octreotide LAR Formulation (EASI)

Introduction: A new formulation of octreotide LAR (OCT LAR) with a new diluent has been developed to facilitate the preparation and administration.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Coriat R

Authors: Cadiot G, Coriat R, Raverot G, Nguyen Tan Hon T, Raingeard I,

Keywords: Octreotide LAR, NET, Acromegaly, Nurse,